Moderna’s mRNA-1345 RSV Vaccine: Concerns over Efficacy and Market Impact

© Reuters

On Thursday, TD Cowen maintained its “Market Perform” rating and $75.00 price target on Moderna (NASDAQ:MRNA), citing concerns about potentially faster declines in the efficacy of its mRNA-1345 RSV vaccine in comparison with its competitors. Moderna’s vaccine showed a 25% decline in efficacy after 8.6 months, in contrast to GlaxoSmithKline’s (GSK) 7% decline after 14 months and mixed results from Pfizer.

Moderna’s mRNA-1345, targeting the F prefusion protein, similar to GSK’s Arexvy, indicated an overall vaccine efficacy against moderate to severe RSV symptoms of 63.3% at a median follow-up of 8.6 months. This represented a significant decrease from the 84% efficacy reported during the first interim analysis. In comparison, the efficacy of GSK’s Arexvy only decreased slightly over a longer period, while Pfizer’s Abrysvo showed a more significant decline in efficacy against two-symptom disease over 17 months.

The results of the Phase III trial, detailed in the ReSViNET 2024 summary, have raised concerns about the durability of Moderna’s vaccine. Initial data had been comparable to GSK’s results and superior to Pfizer’s on some measures. However, recent findings suggest that the effectiveness of Moderna’s vaccine may be declining more rapidly, although this will require further confirmation with additional data.

Both Moderna’s mRNA-1345 and GSK’s Arexvy are adjuvanted vaccines, a characteristic they share that could influence their comparative tolerability profiles. The Pfizer vaccine, for its part, is a non-adjuvanted bivalent protein vaccine, targeting both RSV-A and RSV-B. Different approaches to vaccine design are a factor in the ongoing evaluation of their respective efficacies.

TD Cowen’s report highlights the need for more data to confirm observed trends in vaccine effectiveness. The potential for a more rapid decline in the protective effects of Moderna’s mRNA-1345 could impact its competitive position in the RSV vaccine market, which is an important consideration for both investors and healthcare providers. .

InvestingPro Perspectives

As Moderna (NASDAQ:MRNA) faces scrutiny over the effectiveness of its RSV vaccine mRNA-1345, InvestingPro’s financial metrics provide a broader picture of the company’s current position in the market. Moderna’s market capitalization stands at $35.47 billion, reflecting investors’ valuation of the company amid these concerns. Despite the problems posed by its respiratory syncytial virus vaccine, Moderna’s financial health appears strong, with more cash than debt on its balance sheet, a reassuring sign for investors concerned about the company’s ability to weather market uncertainties.

If we look at the company’s results, Moderna has experienced a significant decline in revenue in the last twelve months until the third quarter of 2023, with a -57.36% drop. This could be indicative of broader challenges facing the company beyond concerns about the effectiveness of the RSV vaccine. However, the company’s share price has seen a strong return in the last three months, up 39.19%, suggesting investors may be looking beyond near-term headwinds.

One tip from InvestingPro that stands out is that Moderna’s management has been buying back actions aggressively, which is usually a sign of confidence on the part of the leadership in the future prospects of the company. Additionally, analysts have revised upward its earnings for the coming period, indicating possible optimism about Moderna’s financial results in the future. Investors looking for a more in-depth analysis have 6 other tips from InvestingPro available, offering a complete view of the company’s financial health and market potential.

Investors interested in delving deeper into these analyzes can use the coupon code SFY24 to get an additional 10% discount on InvestingPro+ subscription for 2 years, or SFY241 to get an additional 10% discount on subscription to InvestingPro+ for 1 year. These subscriptions offer valuable tools and data to make informed investment decisions.